Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

NCT03553550 is registered in ClinicalTrials.gov with Addario Lung Cancer Medical Institute as lead sponsor.

NCT NCT03553550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03553550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
Lead sponsor
Addario Lung Cancer Medical Institute
Phase
Observational
Overall status
Terminated
Start date
June 1, 2018
Completion date
November 15, 2020
Enrollment
38 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer